Literature DB >> 24466591

Searching for a successful HDL-based treatment strategy.

Srinivasa T Reddy, Mohamad Navab, G M Anantharamaiah, Alan M Fogelman.   

Abstract

Despite strong evidence that HDL-cholesterol levels predict atherosclerotic events in a population, attempts at using and HDL-based treatment strategy have not yet been successful. Most of the efforts to date have focused on raising plasma HDL-cholesterol levels. This brief review focuses on a different strategy, which is based on the use of 18-amino acid apoA-I-mimetic peptides. The story of these peptides spans decades and illustrates the remarkable complexity of HDL-based treatment strategies, but suggests that such a strategy may still be successful.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24466591

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

Review 1.  Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review.

Authors:  C Roger White; David W Garber; G M Anantharamaiah
Journal:  J Lipid Res       Date:  2014-08-25       Impact factor: 5.922

2.  Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis.

Authors:  Mohamad Navab; Arnab Chattopadhyay; Greg Hough; David Meriwether; Spencer I Fogelman; Alan C Wagner; Victor Grijalva; Feng Su; G M Anantharamaiah; Lin H Hwang; Kym F Faull; Srinivasa T Reddy; Alan M Fogelman
Journal:  J Lipid Res       Date:  2015-02-02       Impact factor: 5.922

Review 3.  Synthetic high-density lipoprotein-like nanoparticles as cancer therapy.

Authors:  Kaylin M McMahon; Linda Foit; Nicholas L Angeloni; Francis J Giles; Leo I Gordon; C Shad Thaxton
Journal:  Cancer Treat Res       Date:  2015

4.  A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE-/- mice.

Authors:  Sanhu Gou; Li Wang; Chao Zhong; Xinyue Chen; Xu Ouyang; Beibei Li; Guangjun Bao; Hui Liu; Yun Zhang; Jingman Ni
Journal:  Br J Pharmacol       Date:  2020-09-09       Impact factor: 8.739

5.  Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension.

Authors:  David J Ross; Greg Hough; Susan Hama; Jamil Aboulhosn; John A Belperio; Rajan Saggar; Brian J Van Lenten; Abbas Ardehali; Mansoureh Eghbali; Srinivasa Reddy; Alan M Fogelman; Mohamad Navab
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

6.  HDL Cholesterol Efflux is Impaired in Older Patients with Early Sepsis: A Subanalysis of a Prospective Pilot Study.

Authors:  Faheem W Guirgis; Christiaan Leeuwenburgh; Victor Grijalva; Jennifer Bowman; Colleen Kalynych; Lyle Moldawer; Frederick A Moore; Srinivasa T Reddy
Journal:  Shock       Date:  2018-07       Impact factor: 3.454

Review 7.  Synthetic high-density lipoprotein-like nanoparticles for cancer therapy.

Authors:  Linda Foit; Francis J Giles; Leo I Gordon; Colby Shad Thaxton
Journal:  Expert Rev Anticancer Ther       Date:  2014-12-09       Impact factor: 4.512

8.  The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.

Authors:  C Roger White; Geeta Datta; Landon Wilson; Mayakonda N Palgunachari; G M Anantharamaiah
Journal:  Chem Phys Lipids       Date:  2019-01-29       Impact factor: 3.329

Review 9.  ApoA-I-Directed Therapies for the Management of Atherosclerosis.

Authors:  John S Millar; Marina Cuchel
Journal:  Curr Atheroscler Rep       Date:  2015-10       Impact factor: 5.113

Review 10.  Apolipoprotein A-I mimetics.

Authors:  Srinivasa T Reddy; Mohamad Navab; Gattadahalli M Anantharamaiah; Alan M Fogelman
Journal:  Curr Opin Lipidol       Date:  2014-08       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.